Ho AD - Search Results

1

Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET.

Kasper B, Egerer G, Gronkowski M, Haufe S, Lehnert T, Eisenhut M, Mechtersheimer G, Ho AD, Haberkorn U. Kasper B, et al. Among authors: ho ad. Leuk Lymphoma. 2007 Apr;48(4):746-53. doi: 10.1080/10428190601113568. Leuk Lymphoma. 2007. PMID: 17454633

2

Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography.

Kasper B, Dietrich S, Dimitrakopoulou-Strauss A, Strauss LG, Haberkorn U, Ho AD, Egerer G. Kasper B, et al. Among authors: ho ad. Onkologie. 2008 Mar;31(3):107-12. doi: 10.1159/000113795. Epub 2008 Feb 8. Onkologie. 2008. PMID: 18322413 Clinical Trial.

3

The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin.

Kasper B, Schmitt T, Wuchter P, Dimitrakopoulou-Strauss A, Ho AD, Egerer G. Kasper B, et al. Among authors: ho ad. Mar Drugs. 2009 Jul 17;7(3):331-40. doi: 10.3390/md7030331. Mar Drugs. 2009. PMID: 19841717 Free PMC article.

4

[Positron emission tomography as a tool for early prediction of therapy outcome in soft tissue sarcoma].

Kasper B, Schmitt T, Wuchter P, Ho AD, Egerer G. Kasper B, et al. Among authors: ho ad. Dtsch Med Wochenschr. 2009 Sep;134(39):1922-6. doi: 10.1055/s-0029-1237531. Epub 2009 Sep 16. Dtsch Med Wochenschr. 2009. PMID: 19760551 German.

5

Autologous bone marrow transplantation in adult patients with acute lymphoblastic leukemia.

Egerer G, Goldschmidt H, Zoz M, Ho AD. Egerer G, et al. Among authors: ho ad. Leuk Lymphoma. 2003 Jan;44(1):9-14. doi: 10.1080/1042819021000040242. Leuk Lymphoma. 2003. PMID: 12691137 Review.

6

Dose-intensive chemotherapy with stem cell support as a treatment strategy for bone and soft-tissue sarcomas.

Kasper B, Ho AD, Egerer G. Kasper B, et al. Among authors: ho ad. Curr Stem Cell Res Ther. 2006 Jan;1(1):29-35. doi: 10.2174/157488806775269098. Curr Stem Cell Res Ther. 2006. PMID: 18220851

7

Large institutional experience with dose-intensive chemotherapy and stem cell support in the management of sarcoma patients.

Kasper B, Dietrich S, Mechtersheimer G, Ho AD, Egerer G. Kasper B, et al. Among authors: ho ad. Oncology. 2007;73(1-2):58-64. doi: 10.1159/000120629. Epub 2008 Mar 11. Oncology. 2007. PMID: 18334832

8

A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma.

Schmitt T, Lehner B, Kasper B, Bischof M, Roeder F, Dietrich S, Dimitrakopoulou-Strauss A, Strauss LG, Mechtersheimer G, Wuchter P, Ho AD, Egerer G. Schmitt T, et al. Among authors: ho ad. BMC Cancer. 2011 Dec 7;11:510. doi: 10.1186/1471-2407-11-510. BMC Cancer. 2011. PMID: 22152120 Free PMC article. Clinical Trial.

9

Remarkable response to rituximab in a 72-year-old patient with refractory non-Hodgkin's lymphoma and marrow aplasia.

Egerer G, Sauerland K, Ho AD. Egerer G, et al. Among authors: ho ad. Leuk Lymphoma. 2001 Jul;42(3):551-3. doi: 10.3109/10428190109064616. Leuk Lymphoma. 2001. PMID: 11699424

10

Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma?

Kasper B, Ho AD, Egerer G. Kasper B, et al. Among authors: ho ad. Oncology. 2005;68(2-3):115-21. doi: 10.1159/000085704. Epub 2005 May 9. Oncology. 2005. PMID: 15886503 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

720 results

Search Page

Filters